WallStreetZenWallStreetZen

NASDAQ: ALGS
Aligos Therapeutics Inc Stock

$0.67+0.03 (+4.69%)
Updated Feb 21, 2024
ALGS Price
$0.67
Fair Value Price
N/A
Market Cap
$49.90M
52 Week Low
$0.54
52 Week High
$1.76
P/E
-0.35x
P/B
0.91x
P/S
1.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.39M
Earnings
-$81.67M
Gross Margin
100%
Operating Margin
-517.62%
Profit Margin
-498.5%
Debt to Equity
0.57
Operating Cash Flow
-$73M
Beta
1.02
Next Earnings
Mar 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALGS Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to address unmet medical needs in viral and liver diseases. Aligos uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its lead drug candidates are ALG-010133, ALG-000184, ALG-020572, ALG-055009, as well as siRNA -based candidates, ALG-125755, ALG-125097, ALG-125819. Aligos was incorporated in 2018 and is headquartered in South San Francisco, CA.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALGS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALGS is good value based on its book value relative to its share price (0.91x), compared to the US Biotechnology industry average (5.97x)
P/B vs Industry Valuation
ALGS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALGS due diligence checks available for Premium users.

Be the first to know about important ALGS news, forecast changes, insider trades & much more!

ALGS News

Valuation

ALGS fair value

Fair Value of ALGS stock based on Discounted Cash Flow (DCF)
Price
$0.67
Fair Value
$2.52
Undervalued by
73.45%
ALGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALGS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.35x
Industry
16.04x
Market
28.8x

ALGS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
5.97x
ALGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALGS's financial health

Profit margin

Revenue
$3.2M
Net Income
-$18.0M
Profit Margin
-557%
ALGS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALGS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$85.9M
Liabilities
$31.0M
Debt to equity
0.57
ALGS's short-term assets ($74.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALGS's short-term assets ($74.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$20.3M
Investing
-$9.0k
Financing
-$21.0k
ALGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALGS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALGS$49.90M+4.06%-0.35x0.91x
ACHL$50.16M+13.89%-0.65x0.33x
FIXX$50.40M+5.58%-0.38x0.57x
MTNB$50.41M-2.93%-2.11x2.18x
DTIL$49.00M-4.56%-0.65x1.69x

Aligos Therapeutics Stock FAQ

What is Aligos Therapeutics's quote symbol?

(NASDAQ: ALGS) Aligos Therapeutics trades on the NASDAQ under the ticker symbol ALGS. Aligos Therapeutics stock quotes can also be displayed as NASDAQ: ALGS.

If you're new to stock investing, here's how to buy Aligos Therapeutics stock.

What is the 52 week high and low for Aligos Therapeutics (NASDAQ: ALGS)?

(NASDAQ: ALGS) Aligos Therapeutics's 52-week high was $1.76, and its 52-week low was $0.54. It is currently -62.16% from its 52-week high and 23.56% from its 52-week low.

How much is Aligos Therapeutics stock worth today?

(NASDAQ: ALGS) Aligos Therapeutics currently has 74,931,848 outstanding shares. With Aligos Therapeutics stock trading at $0.67 per share, the total value of Aligos Therapeutics stock (market capitalization) is $49.90M.

Aligos Therapeutics stock was originally listed at a price of $14.85 in Oct 16, 2020. If you had invested in Aligos Therapeutics stock at $14.85, your return over the last 3 years would have been -95.52%, for an annualized return of -64.47% (not including any dividends or dividend reinvestments).

How much is Aligos Therapeutics's stock price per share?

(NASDAQ: ALGS) Aligos Therapeutics stock price per share is $0.67 today (as of Feb 21, 2024).

What is Aligos Therapeutics's Market Cap?

(NASDAQ: ALGS) Aligos Therapeutics's market cap is $49.90M, as of Feb 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aligos Therapeutics's market cap is calculated by multiplying ALGS's current stock price of $0.67 by ALGS's total outstanding shares of 74,931,848.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.